Evaluation of the Safety of 500 Mg Intravenous Push Thiamine at a Tertiary Academic Medical Center

Overview

Journal Sci Prog

Publisher Sage Publications

Specialty Science

Date 2022 May 2

PMID 35491726

Authors

Mohammed Aldhaeefi

Kevin McLaughlin

Melanie Goodberlet

Paul Szumita

Affiliations

Soon will be listed here.

Abstract

Thiamine, also known as vitamin B1, is an essential water-soluble micronutrient. Although thiamine has minimal safety concerns, parenteral administration has been associated with rare cases of anaphylactic shock, cardiac arrest, and injection site reaction. The objective of this analysis is to evaluate the incidence of anaphylaxis and injection site reactions associated with the administration of thiamine 500 mg as an intravenous (IV) push in adult patients. This single-center, retrospective analysis was performed at Brigham and Women's Hospital in Boston, Massachusetts. Electronic health records were used to identify all adult patients who were ordered for thiamine 500 mg IV push between July 1, 2020, and December 31, 2020. For the major and minor endpoints, anaphylaxis and injection site reactions were assessed, respectively. Descriptive statistics were used as appropriate. A total of 463 doses of thiamine in 69 patients were evaluated. Thiamine was administered peripherally for 392 (84.7%) doses and centrally for 68 (14.7) doses. No anaphylactic reactions were observed. A total of 4 injection site reactions (0.86%) were noted with 4 unique doses. All reactions were classified as low-grade based on our institutional grading system. All injection site reactions were classified as "possible" (Naranjo score of 1-4). Administration of IV push 500 mg thiamine was not associated with anaphylactic events and was associated with a low rate of injection site reactions.

References

Kirschenbaum B, Cacace L, Anderson R, Ackerman L . Personnel time and preparation costs for compounded versus premixed intravenous admixtures in three community hospitals. Am J Hosp Pharm. 1988; 45(3):605-8. View

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

Muraro A, Roberts G, Worm M, Bilo M, Brockow K, Rivas M . Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014; 69(8):1026-45. DOI: 10.1111/all.12437. View

McLaughlin K, Joyal K, Lee S, Corrado M, Marquis K, Anger K . Safety of intravenous push thiamine administration at a tertiary academic medical center. J Am Pharm Assoc (2003). 2020; 60(4):598-601. DOI: 10.1016/j.japh.2019.12.005. View

Plumridge R, Maher M . Justification of a pharmacy intravenous admixture service in an Australian hospital. Am J Hosp Pharm. 1993; 50(3):463-6. View

Reynolds D, Johnson M, Longe R . Medication delivery time requirements in centralized and decentralized unit dose drug distribution systems. Am J Hosp Pharm. 1978; 35(8):941-3. View

Lonsdale D . A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. Evid Based Complement Alternat Med. 2006; 3(1):49-59. PMC: 1375232. DOI: 10.1093/ecam/nek009. View

Flannery A, Adkins D, Cook A . Unpeeling the Evidence for the Banana Bag: Evidence-Based Recommendations for the Management of Alcohol-Associated Vitamin and Electrolyte Deficiencies in the ICU. Crit Care Med. 2016; 44(8):1545-52. DOI: 10.1097/CCM.0000000000001659. View

Thomson A, Cook C, Touquet R, Henry J . The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department. Alcohol Alcohol. 2002; 37(6):513-21. DOI: 10.1093/alcalc/37.6.513. View

10.

Gorski L . The 2016 Infusion Therapy Standards of Practice. Home Healthc Now. 2016; 35(1):10-18. DOI: 10.1097/NHH.0000000000000481. View

11.

Osman M, Casey P . Angioneurotic oedema secondary to oral thiamine. BMJ Case Rep. 2013; 2013. PMC: 3794222. DOI: 10.1136/bcr-2013-200558. View

12.

Juel J, Pareek M, Langfrits C, Jensen S . Anaphylactic shock and cardiac arrest caused by thiamine infusion. BMJ Case Rep. 2013; 2013. PMC: 3736362. DOI: 10.1136/bcr-2013-009648. View

13.

Whitfield K, Bourassa M, Adamolekun B, Bergeron G, Bettendorff L, Brown K . Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci. 2018; 1430(1):3-43. PMC: 6392124. DOI: 10.1111/nyas.13919. View

14.

Tjugum S, Hedrick T, Jean S, Heeney S, Rohde K, Campbell-Bright S . Evaluation of the Safety of Intravenous Thiamine Administration in a Large Academic Medical Center. J Pharm Pract. 2019; 34(3):397-402. DOI: 10.1177/0897190019872584. View

15.

Webster J, McGrail M, Marsh N, Wallis M, Ray-Barruel G, Rickard C . Postinfusion Phlebitis: Incidence and Risk Factors. Nurs Res Pract. 2015; 2015:691934. PMC: 4446485. DOI: 10.1155/2015/691934. View

16.

Dhir S, Tarasenko M, Napoli E, Giulivi C . Neurological, Psychiatric, and Biochemical Aspects of Thiamine Deficiency in Children and Adults. Front Psychiatry. 2019; 10:207. PMC: 6459027. DOI: 10.3389/fpsyt.2019.00207. View